Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 111 publications
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.
Journal: medRxiv : the preprint server for health sciences
Published: September 05, 2025
Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets.
Journal: NPJ breast cancer
Published: October 04, 2024
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 03, 2024
Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma.
Journal: American journal of clinical oncology
Published: March 14, 2024
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: August 18, 2022
Oligometastatic Breast Cancer Patients Treated with High-Dose Chemotherapy and Targeted Radiation: Long-Term Follow-Up of a Phase II Trial.
Journal: Cancers
Published: August 11, 2022
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Journal: Cancer
Published: August 09, 2022
Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer.
Journal: Cancers
Published: July 26, 2022
Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review.
Journal: Frontiers in oncology
Published: July 26, 2022
Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.
Journal: Science translational medicine
Published: July 20, 2022
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 19, 2022
Last Updated: 09/26/2026